Susanna Scarpa Selected Research

Kinesins

1/2022	The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells.
1/2018	The kinesin Eg5 inhibitor K858 induces apoptosis and reverses the malignant invasive phenotype in human glioblastoma cells.
1/2018	Growth arrest and apoptosis induced by kinesin Eg5 inhibitor K858 and by its 1,3,4-thiadiazoline analogue in tumor cells.
1/2016	The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells.
11/2015	Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Susanna Scarpa Research Topics

Disease

21	Neoplasms (Cancer) 04/2022 - 09/2004
15	Breast Neoplasms (Breast Cancer) 01/2022 - 10/2005
6	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 08/2003
4	Carcinoma (Carcinomatosis) 01/2022 - 05/2005
4	Neoplasm Metastasis (Metastasis) 05/2014 - 08/2003
3	Inflammation (Inflammations) 04/2022 - 01/2013
3	Melanoma (Melanoma, Malignant) 01/2022 - 01/2003
3	Gaucher Disease (Gaucher's Disease) 08/2015 - 08/2010
2	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2018
2	Squamous Cell Carcinoma of Head and Neck 01/2022 - 06/2021
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 06/2021
2	Circulating Neoplastic Cells 01/2021 - 05/2019
2	Disease Progression 05/2019 - 01/2015
2	Brain Neoplasms (Brain Tumor) 01/2018 - 08/2014
2	Cardiotoxicity 01/2017 - 03/2016
2	Heart Failure 03/2016 - 08/2006
2	Ovarian Neoplasms (Ovarian Cancer) 01/2016 - 11/2015
2	Fibroadenoma 01/2013 - 10/2005
2	Infarction (Infarctions) 09/2007 - 03/2004
2	Mesothelioma 09/2004 - 01/2002
1	Hyperglycemia 04/2022
1	Insulin Resistance 04/2022
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022
1	Sjogren's Syndrome (Sjogren Syndrome) 01/2022
1	Glioma (Gliomas) 12/2019
1	Hyperthyroidism 11/2017
1	Hypoxia (Hypoxemia) 11/2017
1	Pathologic Complete Response 01/2017

Drug/Important Bio-Agent (IBA)

8	SurvivinIBA 01/2018 - 01/2003
5	KinesinsIBA 01/2022 - 11/2015
5	Taxoids (Taxanes)IBA 07/2017 - 10/2015
4	Fibronectins (Fibronectin)IBA 11/2017 - 01/2002
4	Phenobarbital (Luminal)FDA Link 09/2017 - 01/2016
3	Antineoplastic Agents (Antineoplastics)IBA 06/2021 - 11/2015
3	Biomarkers (Surrogate Marker)IBA 07/2017 - 10/2015
3	AnthracyclinesIBA 07/2017 - 03/2016
3	taxaneIBA 01/2017 - 10/2015
3	Progesterone Receptors (Progesterone Receptor)IBA 02/2016 - 10/2005
3	SaposinsIBA 08/2015 - 08/2010
2	EnzymesIBA 04/2022 - 01/2013
2	Caspase 3 (Caspase-3)IBA 01/2022 - 03/2004
2	AndrogensIBA 01/2021 - 01/2013
2	Androgen Receptors (Androgen Receptor)IBA 01/2021 - 05/2019
2	Temozolomide (Temodar)FDA LinkGeneric 12/2019 - 01/2018
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2019 - 10/2015
2	Messenger RNA (mRNA)IBA 05/2019 - 01/2013
2	Antimitotic AgentsIBA 01/2018 - 11/2015
2	Proteins (Proteins, Gene)FDA Link 01/2018 - 07/2017
2	Trastuzumab (Herceptin)FDA Link 07/2017 - 03/2016
2	Docetaxel (Taxotere)FDA Link 02/2016 - 10/2015
2	Estrogen ReceptorsIBA 02/2016 - 08/2014
2	CytokinesIBA 10/2015 - 01/2013
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 10/2015 - 06/2006
2	LipidsIBA 08/2015 - 08/2010
2	Glucosylceramides (Glucocerebrosides)IBA 08/2015 - 08/2010
2	Diphosphonates (Bisphosphonates)IBA 05/2014 - 06/2006
2	Zoledronic Acid (Zometa)FDA Link 05/2014 - 08/2003
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 04/2007 - 05/2005
2	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2007 - 11/2004
2	TenascinIBA 10/2005 - 09/2004
2	Laminin (Merosin)IBA 10/2005 - 01/2002
1	AntagomirsIBA 04/2022
1	Sirtuin 1IBA 04/2022
1	Oxygen (Dioxygen)IBA 04/2022
1	Glycyrrhizic Acid (Glycyrrhizin)IBA 04/2022
1	SirtuinsIBA 04/2022
1	Glucose (Dextrose)FDA LinkGeneric 04/2022
1	ResveratrolIBA 04/2022
1	TubulinIBA 01/2022
1	Cell Adhesion MoleculesIBA 01/2022
1	Annexin A5IBA 01/2022
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2022
1	Propidium (Propidium Iodide)IBA 01/2022
1	Lysosomal Membrane ProteinsIBA 01/2022
1	belimumabIBA 01/2022
1	B-Cell Activating FactorIBA 01/2022
1	CarbamatesIBA 06/2021
1	EstersIBA 06/2021
1	Cyclin B1IBA 06/2021
1	NitrogenIBA 01/2020
1	MethyltransferasesIBA 12/2019
1	abirateroneIBA 05/2019
1	enzalutamideIBA 05/2019
1	Triiodothyronine (Liothyronine)FDA LinkGeneric 11/2017
1	Everolimus FDA Link 09/2017
1	TOR Serine-Threonine KinasesIBA 09/2017
1	exemestane (Aromasin)FDA Link 09/2017
1	Apoptosis Regulatory ProteinsIBA 09/2017
1	Hormones (Hormone)IBA 09/2017
1	Neuregulin-1 (Neuregulin 1)IBA 07/2017
1	Galectin 3 (LGALS3)IBA 07/2017
1	Carboplatin (JM8)FDA LinkGeneric 01/2017
1	human ERBB2 proteinIBA 03/2016

Therapy/Procedure

11	Therapeutics 04/2022 - 05/2005
8	Drug Therapy (Chemotherapy) 12/2019 - 10/2014
2	Prostatectomy (Retropubic Prostatectomy) 01/2021 - 01/2013
2	Castration 01/2021 - 05/2019
1	Radiotherapy 12/2019
1	Aftercare (After-Treatment) 07/2017
1	Neoadjuvant Therapy 01/2017